Who We Are2019-02-21T14:44:08+00:00

Singulex Is Revolutionizing Immunodiagnostics to Transform Healthcare

Singulex is an immunodiagnostics company at the forefront of Single Molecule Counting technology, a novel immunoassay technology recognized for unprecedented ultra-sensitivity in the precision measurement of biomarkers. Singulex is the developer of the Singulex Clarity system, a fully automated, in vitro diagnostics platform powered by Single Molecule Counting technology. With up to 1000 times more sensitivity than existing technologies, Single Molecule Counting reveals the presence or absence of disease more clearly and definitively than was possible before. In October 2018, Singulex introduced into the United States the Singulex Clarity C. diff toxins A/B assay run on the Singulex Clarity system. This rapid, high-sensitivity, high-precision, one-step solution to C. difficile toxin testing matches the sensitivity and specificity of cell cytotoxicity neutralization assay (CCNA), the current gold standard, giving it the potential to reduce the false positives of PCR and the false negatives of current, less sensitive toxin immunoassays. The Singulex Clarity system and the Singulex Clarity C. diff toxins A/B assay are registered and listed with the FDA.

Singulex also works with a number of pharmaceutical partners to provide companion diagnostic development services and is developing a point-of-care platform and exploring applications beyond the clinical setting.

Guido Baechler
Guido BaechlerPresident and Chief Executive Officer
Guido Baechler has served as President and Chief Executive Officer of Singulex since 2013, bringing with him over two decades of experience working with emerging technologies in the life sciences and diagnostics industries. Guido joined Singulex in 2008, serving first as Vice President of Diagnostics and then as Senior Vice President of Operations. Previously, Guido worked at Roche in both the U.S. and Switzerland. He held executive and leadership positions at both Roche Diagnostics and Roche Molecular Diagnostics and gained managerial and functional expertise in research, development and marketing.

Guido holds a B.S. in Electrical Engineering from Fachhochschule Brugg-Windisch in Switzerland. He has completed a series of executive finance and management classes at the London School of Business and the Haas School of Business, University of California, Berkeley.

Jeff Rona
Jeff RonaChief Financial Officer
Jeff joined Singulex in January of 2019, he brings more than 25 years of experience to the role, both as a former investment banker and a strategic financial executive with expertise in operations and transactions for private and public life sciences companies. He previously held senior leadership positions for Great Basin Scientific, GlobeImmune, AlgoRx Pharmaceuticals and Antigenics, and later formed a successful life sciences financial advisory practice. He has raised more than $500 million for start-up companies and also led multiple liquidity events. Jeff is a Managing Director at Danforth Advisors, providing services to life sciences companies.

He began his career at Coopers & Lybrand and UBS Investment Bank, and holds a BS in Accounting from Case Western Reserve University.

Jeffrey Bishop, Ph.D.
Jeffrey Bishop, Ph.D.Chief Scientific Officer
Jeff Bishop joined Singulex in 2013. Jeff has worked in the diagnostics industry for more than 13 years at Biosite, Inverness Medical Innovations and Alere. During this time, Jeff held various scientific and leadership positions within the R&D organization including Vice President of R&D for Point of Care platforms and Vice President of R&D for Drugs of Abuse platforms. Jeff has extensive experience working with biomarkers and has led the development of many drug and biomarker assays on numerous platforms across a wide range of disease states.

Jeff earned both an M.S. and a Ph.D. in Bioengineering from the University of California, San Diego and holds a B.S. in Chemical Engineering from Brigham Young University. He also holds an RAC certification in Regulatory Affairs.

Darin Leigh
Darin LeighChief Commercial Officer
Darin Leigh has joined Singulex in 2018. Darin has worked in the life science and IVD industries for over 25 years, for Abbott, Luminex, Asuragen and Metabalon; in senior roles focusing on commercial operations, global sales and marketing. As a senior executive, he has extensive experience in building commercial businesses from the group up, and delivering accelerated sales growth and profitability.

Darin earned a degree in Medical Laboratory Sciences from Paddington College, University of London, United Kingdom.

John Todd, Ph.D.
John Todd, Ph.D.SVP, Corporate Development
John Todd joined Singulex in 2007 and has championed Singulex’s clinical programs to demonstrate the clinical utility of SMC™ for cardiovascular disease risk prediction and patient management. John has substantial diagnostics development experience, having developed products to address unmet clinical needs in numerous disease areas and successfully establishing their medical advantage.

Prior to joining Singulex, John held leadership and executive positions at numerous healthcare companies including Chiron Diagnostics, Bayer Diagnostics, Baxter Healthcare, NUGEN Technologies, Protogene Labs and ENZO Biochem. He has co-authored over 60 peer-reviewed publications and 90 scientific abstracts, been issued 15 patents and presented at over 100 biomedical scientific conferences. John has received 6 SBIR grants for the development and commercialization of diagnostic products.

John received a Ph.D. in Biochemistry and a B.S. in Biology from the University of Southern California, followed by post graduate training in Cell and Molecular Biology at the Sabatini Lab, New York University Medical Center.

Patricia Ryan
Patricia RyanCompliance Officer
Patricia Ryan joined Singulex in 2014, bringing over 20 years of experience focused on the internal control environment. Most recently, Patty served as the Latin American and Asia Pacific Regional Compliance Officer for Novartis Vaccines & Diagnostics as well as the U.S. Compliance Officer for the Diagnostics business, providing compliance support in all aspects of commercial activities. Patty joined Novartis Vaccines & Diagnostics as a Sarbanes- Oxley Compliance; Internal Controls Analyst. Patty also spent several years as a Corporate Internal Auditor for AT&T.

Patty has worked for over a decade in local Public Accounting Firms in the San Francisco Bay area leading auditing and consulting service engagements. Patty holds a B.S. in Business Administration with a concentration in Accounting from San Jose State University. She is a Certified Public Accountant and a Certified Internal Auditor.

Bill Hammack
Bill HammackVP, Human Resources
William Hammack comes to Singulex with over forty five years of experience in the human resource field. He has provided service to employees of companies of a few hundred to tens of thousands, with operations around the world. His background includes creating and managing Human Resource departments and programs for startup companies as well as managing all H.R. responsibilities for multi-national public organizations. He has worked in Europe, Asia and the Middle East.

Mr. Hammack has been a Vice President/Senior Human Resource Officer for more than thirty five years. Servicing such companies as General Electric Medical Systems, Diasonics, Elbit Medical Systems and Komag Inc.

He holds a BA in Public Policy/Administration from San Diego State University.

Guido Baechler
Guido BaechlerPresident and Chief Executive Officer
Guido Baechler has served as President and Chief Executive Officer of Singulex since 2013, bringing with him over two decades of experience working with emerging technologies in the life sciences and diagnostics industries. Guido joined Singulex in 2008, serving first as Vice President of Diagnostics and then as Senior Vice President of Operations. Previously, Guido worked at Roche in both the U.S. and Switzerland. He held executive and leadership positions at both Roche Diagnostics and Roche Molecular Diagnostics and gained managerial and functional expertise in research, development and marketing.

Guido holds a B.S. in Electrical Engineering from Fachhochschule Brugg-Windisch in Switzerland. He has completed a series of executive finance and management classes at the London School of Business and the Haas School of Business, University of California, Berkeley.

David Ian Bell
David Ian BellChief Innovation Officer, Grifols
David Ian Bell is the Chief Innovation Officer for Grifols S.A. Additionally, he is the President and Chief Executive Officer of Grifols Innovation and New Technology Limited (GIANT). He also serves as General Counsel with responsibility for, among other things, mergers and acquisitions and new business development. Mr. Bell serves on Grifols Corporate, Bioscience, Diagnostic and Hospital Executive Committees and is on the Board of Directors of numerous Grifols’ portfolio companies including Alkahest, Aradigm, Singulex, and Araclon.

Prior to joining Grifols in 2003, Mr. Bell served as General Counsel and Vice President of Alpha Therapeutic Corporation following more than 20 years as a corporate lawyer specializing in healthcare, pharmaceutical and biotechnology regulation and liability. Mr. Bell attended the University of California, Irvine focusing on Psychobiology (Neuroscience), Southwestern University School of Law and a postgraduate program at Harvard Law School.

Heiner Dreismann, Ph.D.
Heiner Dreismann, Ph.D.Lead Director
Heiner Dreismann, Ph.D. has been a member of our board of directors since June of 2007 and has over 26 years of experience in biotech and healthcare companies. Since May of 2008, Dr. Dreismann has served as Interim Chief Executive Officer of GeneNews Limited, a public diagnostics company. From 2001 until 2006, Dr. Dreismann served as President and Chief Executive Officer of Roche Molecular Systems, Inc., a division of Hoffmann-La Roche Ltd., or Roche, focused on clinical molecular diagnostics.

Before serving in these roles, he held various management positions in Roche, among them Head of Integration Office Diagnostics and Head of Global Business Development for Roche Diagnostics. Dr. Dreismann currently serves on the boards of directors of Ignyta, Inc., Myriad Genetics, Inc., Med BioGene Inc. and GeneNews Ltd., each a public company in the life sciences or healthcare diagnostics sectors. Dr. Dreismann received his M.A. in Biology and his Ph.D. in Microbiology / Molecular Biology both from Westfaelische Wilhelms University (The University of Münster) in Germany. Dr. Dreismann brings to our board of directors significant expertise in the biotech and healthcare sectors from both his advanced degree and from previous executive leadership positions. In addition, Dr. Dreismann’s experience as a Director of public life sciences companies provides the board of directors with valuable insights to assist in achieving our goals.

Carl L. Gordon, Ph.D., CFA
Carl L. Gordon, Ph.D., CFAGeneral Partner, OrbiMed and Co-Head, Private Equity
Carl Gordon, Ph.D., CFA has been a member of our board of directors since June of 2007. Dr. Gordon co-founded OrbiMed Advisors LLC, or OrbiMed, where he serves as a General Partner and Co-Head of Private Equity. He is experienced in both private equity and small-capitalization public equity investments. Prior to his experience at OrbiMed, Dr. Gordon was a senior biotechnology analyst at Mehta and Isaly, a pharmaceutical consulting firm and predecessor to OrbiMed, from 1995 to 1997.

From 1993 to 1995, Dr. Gordon was a fellow at The Rockefeller University. He received his Ph.D. in Molecular Biology from the Massachusetts Institute of Technology and a bachelor’s degree from Harvard College.

From August 2009 until June 2012, Dr. Gordon also served on the board of directors of Complete Genomics, Inc., a life sciences company. As a venture capitalist focused on life science companies who sits on numerous boards, Dr. Gordon provides financial and operational expertise regarding our industry. In addition, Dr. Gordon provides substantial expertise in the particularly relevant scientific field of molecular biology, and his financial credentials are valuable toward his service on our audit committee.

Stephen L. Rose, CPA, CMA
Stephen L. Rose, CPA, CMADirector, Fisk Ventures, LLC
Steve Rose, CPA, CMA, has been a member of our board of directors since September, 2004. Mr. Rose, who has over 17 years of experience in venture investing, is Managing Director of Fisk Ventures, LLC, the venture investment company for H. Fisk Johnson, Ph.D., Chairman of the Board, Chairman and Chief Executive Officer of S.C. Johnson and Son Inc., or S.C. Johnson. In this capacity, Mr. Rose serves on the boards of several early stage technology-based companies. Mr. Rose previously held several positions with S.C. Johnson in both the United States and in Canada, including positions in strategic planning, new business and new product development, and financial and business management.

Mr. Rose has an Honors Bachelor of Commerce from McMaster University, and is also a Certified Management Accountant. As a venture capitalist with experience on the boards of several emerging companies, Mr. Rose provides the Singulex Board of Directors with insightful and relevant expertise in both finance and operations. In addition, his financial credentials and experience are of significant value in his service on our governance committee.

Fred K. Vogt
Fred K. VogtPresident, FKV Enterprises, LLC
Fred Vogt has been a member of our board of directors since our incorporation in 2002. Mr. Vogt has 28 years of operations and manufacturing experience in the pharmaceutical industry, and he currently provides consulting services to senior management executives through FKV Enterprises LLC. From 1997 until 2000, Mr. Vogt served as a Senior Vice President of Specialty Chemicals at Tetra Technologies Inc., a chemical manufacturer.

Prior to this experience, he worked for 25 years for Mallinckrodt, Inc., a chemical and pharmaceutical company, in a variety of manufacturing and business positions. Mr. Vogt has a bachelor’s degree in Chemical Engineering, a master’s degree in Engineering Administration and Honorary Professional Chemical Engineering degree from the University of Missouri at Rolla.